Management of MCI in the Outpatient Setting.

IF 5.5 2区 医学 Q1 PSYCHIATRY Current Psychiatry Reports Pub Date : 2024-08-01 Epub Date: 2024-06-10 DOI:10.1007/s11920-024-01514-3
Amy Abramowitz, Michael Weber
{"title":"Management of MCI in the Outpatient Setting.","authors":"Amy Abramowitz, Michael Weber","doi":"10.1007/s11920-024-01514-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>We review current literature related to the clinical assessment of Mild Cognitive Impairment (MCI). We compile recommendations related to the evaluation of MCI and examine literature regarding the use of clinical biomarkers in this assessment, the role of non-pharmacologic therapy in the prevention of cognitive decline, and recent approval of anti-amyloid therapy in the treatment of MCI.</p><p><strong>Recent findings: </strong>The role of imaging and plasma biomarkers in the clinical assessment of MCI has expanded. There is data that non-pharmacologic therapy may have a role in the prevention of neurocognitive decline. Anti-amyloid therapies have recently been approved for clinical use. Clinical assessment of MCI remains multifactorial and includes screening and treating for underlying psychiatric and medical co-morbidities. The use of biomarkers in clinical settings is expanding with the rise of anti-amyloid therapies. These new diagnostics and therapeutics require nuanced discussion of risks and benefits. Psychiatrist's skillset is uniquely suited for these complex evaluations.</p>","PeriodicalId":11057,"journal":{"name":"Current Psychiatry Reports","volume":" ","pages":"413-421"},"PeriodicalIF":5.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Psychiatry Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11920-024-01514-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: We review current literature related to the clinical assessment of Mild Cognitive Impairment (MCI). We compile recommendations related to the evaluation of MCI and examine literature regarding the use of clinical biomarkers in this assessment, the role of non-pharmacologic therapy in the prevention of cognitive decline, and recent approval of anti-amyloid therapy in the treatment of MCI.

Recent findings: The role of imaging and plasma biomarkers in the clinical assessment of MCI has expanded. There is data that non-pharmacologic therapy may have a role in the prevention of neurocognitive decline. Anti-amyloid therapies have recently been approved for clinical use. Clinical assessment of MCI remains multifactorial and includes screening and treating for underlying psychiatric and medical co-morbidities. The use of biomarkers in clinical settings is expanding with the rise of anti-amyloid therapies. These new diagnostics and therapeutics require nuanced discussion of risks and benefits. Psychiatrist's skillset is uniquely suited for these complex evaluations.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在门诊环境中管理 MCI。
综述目的:我们回顾了目前与轻度认知功能障碍(MCI)临床评估相关的文献。我们汇编了与 MCI 评估相关的建议,并研究了有关在该评估中使用临床生物标志物、非药物疗法在预防认知功能衰退中的作用以及最近批准的抗淀粉样蛋白疗法治疗 MCI 的文献:影像和血浆生物标志物在 MCI 临床评估中的作用已经扩大。有数据表明,非药物疗法可在预防神经认知功能衰退方面发挥作用。抗淀粉样蛋白疗法最近已被批准用于临床。MCI 的临床评估仍然是多因素的,包括筛查和治疗潜在的精神和医疗并发症。随着抗淀粉样蛋白疗法的兴起,生物标志物在临床中的应用也在不断扩大。这些新的诊断和治疗方法需要对风险和益处进行细致的讨论。精神科医生的技能非常适合进行这些复杂的评估。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
11.30
自引率
3.00%
发文量
68
审稿时长
6-12 weeks
期刊介绍: This journal aims to review the most important, recently published research in psychiatry. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by psychiatric disorders. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as anxiety, medicopsychiatric disorders, and schizophrenia and other related psychotic disorders. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
期刊最新文献
Children's Nutrition, Eating Behavior, and Mental Health During the COVID-19 Pandemic. Intensifying Substance Use Trends among Youth: A Narrative Review of Recent Trends and Implications. Correction: Harnessing Immersive Virtual Reality: A Comprehensive Scoping Review of its Applications in Assessing, Understanding, and Treating Eating Disorders. Empowering the Vulnerable: The Impact of SEL on Traumatized Children's Academic and Social Outcomes in Crises. Machine Learning for Mental Health: Applications, Challenges, and the Clinician's Role.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1